FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to methods for the treatment of lung cancer. Methods include the selection of a patient with non-small cell lung cancer, where patient’s tumor tissue expresses PD-L1 in ≥50% of tumor cells, and the patient is not tested as positive relatively to mutations of an epidermal growth factor receptor (EGFR), translocations of anaplastic lymphoma kinase (ALK) and/or fusions of ROS1, as well as the injection to the patient of therapeutically effective amount of an antibody specifically binding to PD-1.
EFFECT: invention is effective for the treatment of non-small cell lung cancer.
28 cl, 14 dwg, 13 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| METHODS FOR MODULATING CART-CELLS | 2017 |
|
RU2774232C2 |
| METHOD FOR TREATMENT OF MALIGNANT NEOPLASM, USING COMBINATION OF ANTIBODY TO PD-1 AND CHEMOTHERAPEUTIC AGENT | 2021 |
|
RU2787457C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| METHODS AND COMBINED THERAPEUTIC PRODUCT FOR THE TREATMENT OF BILE DUCTS CANCER | 2019 |
|
RU2793543C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
| ANTI-HUMAN 4-1BB ANTIBODIES AND USE THEREOF | 2018 |
|
RU2725811C1 |
